Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
AstraZeneca
Medtronic
Boehringer Ingelheim

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR FOSCAVIR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Foscavir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Baylor College of Medicine Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Icahn School of Medicine at Mount Sinai Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Johns Hopkins University Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Memorial Sloan Kettering Cancer Center Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Foscavir

Condition Name

Condition Name for Foscavir
Intervention Trials
HIV Infections 7
Cytomegalovirus Retinitis 4
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable 1
Stage IV Adult Immunoblastic Large Cell Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Foscavir
Intervention Trials
HIV Infections 7
Retinitis 5
Cytomegalovirus Retinitis 5
Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Foscavir

Trials by Country

Trials by Country for Foscavir
Location Trials
United States 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Foscavir
Location Trials
California 3
Texas 2
New York 2
Michigan 2
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Foscavir

Clinical Trial Phase

Clinical Trial Phase for Foscavir
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Foscavir
Clinical Trial Phase Trials
Completed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Foscavir

Sponsor Name

Sponsor Name for Foscavir
Sponsor Trials
Johns Hopkins Bloomberg School of Public Health 4
Northwestern University 3
University of California, Los Angeles 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Foscavir
Sponsor Trials
Other 48
NIH 4
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
McKesson
Boehringer Ingelheim
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.